期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Chordoma Sociodemographic, Clinical and Therapeutic Aspects in National Institute of Oncology Rabat Morocco: A Report of 9 Cases
1
作者 Gaël Kietga patricia agbanglanon +3 位作者 Bertrand Compaore Evrard Seka Amine Lachgar Noureddine Benjaafar 《Journal of Cancer Therapy》 2021年第1期47-56,共10页
<strong>Introduction:</strong> <span><span><span style="font-family:""><span style="font-family:Verdana;">Chordoma is a rare bone tumor, which develops main... <strong>Introduction:</strong> <span><span><span style="font-family:""><span style="font-family:Verdana;">Chordoma is a rare bone tumor, which develops mainly from the sacrum, the base of the skull, or the spine. Surgery + radiotherapy (if necessary) is the standard treatment. Data on chordoma are scarce in this re</span><span style="font-family:Verdana;">gion, and thus, here we summarized 9 patients with this tumor whom we</span><span style="font-family:Verdana;"> treated in this institute. </span><b><span style="font-family:Verdana;">Material: </span></b><span style="font-family:Verdana;">Nine chordoma patients were summarized, who were treated in National Institute of Oncology in Rabat between 2013 </span><span style="font-family:Verdana;">and 2018. We retrieved data from medical charts and analyzed the clinical</span><span style="font-family:Verdana;"> characteristics of this tumor. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">The average age was 49 years (range: 29 </span><span style="font-family:Verdana;">- 72), with male: female of 3:6. The manifestation-diagnosis time was 4</span><span style="font-family:Verdana;"> months (range: 2 - 14). Regarding the tumor location, lumbosacral spine;5, the skull;4. Mass was evident in 6. Signs of locoregional compressions (paraparesis or tetraparesis) were observed in 3. As for treatment, a partial tumor excision was performed in 8, with 3 patients undergoing a wide excision. Radiotherapy was done;3 patients with a dose of 46 Gy, 3 patients with 66 Gy, 1 patient with 50 Gy, and 1 patient with a 16 Gy gamma radio-knife in a single session. 4 patients with a dose of 46 Gy, 2 patients with 60 Gy, and 1 patient with a 16 Gy gamma radio-knife in a single session. Of 9, 4 patients had good locoregional control whereas 5 patients had local recurrence. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Chordoma is a predominantly local aggressive tumor with low metastatic potential. The surgical excision remains the main prognostic factor. Advances in radiotherapy may improve local control. These data are of use in management of this tumor in Rabat (Morocco).</span></span></span></span> 展开更多
关键词 CHORDOMA Diagnosis Radiation Therapy Morocco
下载PDF
Palliative Treatment of Locally Advanced Non Metastatic Lung Cancer
2
作者 Gael Kietga Wilfried Mosse +8 位作者 patricia agbanglanon Bertrand Compaore Davy Nchepo Evrard Seka Sanae Elmajjaoui Hanane Elkacemi Tayeb Kebdani Amine Lachgar Noureddine Benjaafar 《Journal of Cancer Therapy》 2021年第2期71-77,共7页
<strong>Introduction</strong><span style="font-family:Verdana;"><strong>: </strong></span><span style="font-family:Verdana;">To determine the proportion an... <strong>Introduction</strong><span style="font-family:Verdana;"><strong>: </strong></span><span style="font-family:Verdana;">To determine the proportion and the reasons which lead to palliative treatment in patients initially a candidate for concomitant chemoradiotherapy (CCRT).</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Methods</span></b><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">A retrospective study including patients followed for locally advanced lung cancer newly diagnosed from April 1, 2016, to 12/31/2017 in the radiotherapy department of the National Oncology Institute who received palliative treatment.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Results</span></b><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">We collected 52 patients out of a total of 225 stage III patients (23%) followed by lung cancer candidates for CCRT who had undergone palliative treatment. The mean age in our series was 61.23 years [22</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">81] with 86% male</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;"> The majority of patients (71%) had Performance Status (PS) ≤ 2. Histological confirmation was obtained by pathological examination in all our patients. It was an adenocarcinoma (ADK) in 54% of cases;squamous cell carcinoma in 46% of cases. The reasons for palliative treatment were mainly due to dosimetric constraints: large tumor volume 22/52 (42%);the tumor location close to the bone marrow in 15 of 52 (29%) patients;and general Performance Status impairment (29%) in 15 of 52 patients. Palliative treatment consisted of palliative chemotherapy in 37 of 52 patients (71%)</span><span style="font-family:Verdana;">, </span><span style="font-family:Verdana;">among whom 19 (51%) were stable after 2 months of chemotherapy, in palliative dose chest radiotherapy on the pulmonary parenchyma and/or mediastinum in 10 of 52 (19%) patients, and supportive care in 5 (10 %) patients. We observed 40/52 (77%) cases of stationary course, 04/52 (8%) cases of progress to metastases, and 08/52 (15%) deaths before radiotherapy.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Conclusion</span></b><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">A large proportion of patients followed for locally advanced non-metastatic lung cancer are not eligible for curative treatment. The reasons for the palliative treatment of patients followed for lung cancer candidates for CCRT are variable but for a large proportion of patients due to the deterioration of their state of health during their diagnostic journey. Hence</span><span style="font-family:Verdana;">,</span><span style="font-family:""> </span><span style="font-family:Verdana;">there is </span><span style="font-family:""><span style="font-family:Verdana;">the need to improve the early diag</span><span style="font-family:Verdana;">nosis and early management of patients with lung cancer to avoid delayed care.</span></span> 展开更多
关键词 Lung Cancer Palliative Treatment Locally Advanced
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部